Andere Sprachen TG Therapeutics, Inc.

Aktien

A1JXW7

US88322Q1085

TGTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 18.04.2024			% 5 Tage	% 1. Jan.
13.99 ^USD	+1.23%		-5.22%	-18.09%

18.04.	TG Therapeutics erhält Auftrag der Veteranenbehörde für das Multiple-Sklerose-Medikament Briumvi	MT
18.04.	Tg Therapeutics, Inc. erhält nationalen Vertrag mit dem Department of Veterans Affairs für Briumvi als bevorzugtes Anti-Cd20-Medikament bei schubförmiger Multipler Sklerose	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	18.04.
Sector Update: Health Care	18.04.
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18.04.
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	18.04.
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis	18.04.
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18.04.
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	16.04.
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	15.04.
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	13.03.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	08.03.
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	04.03.
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	01.03.
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	01.03.
Sector Update: Health Care Stocks Softer Wednesday Afternoon	28.02.
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	28.02.
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	28.02.
TG Therapeutics: Q4 Earnings Snapshot	28.02.
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	28.02.
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results	28.02.
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen TG Therapeutics, Inc.

Aktien

A1JXW7

US88322Q1085

TGTX

Andere Sprachen

Filter